[Congressional Record (Bound Edition), Volume 159 (2013), Part 13]
[Senate]
[Pages 19424-19425]
[From the U.S. Government Publishing Office, www.gpo.gov]




                NATIONAL PEDIATRIC RESEARCH NETWORK ACT

  Mr. WICKER. Mr. President, I wish to celebrate the passage of the 
National Pediatric Research Network Act, a bipartisan piece of 
legislation that was signed into law last month.
  I wish to thank my colleague, Senator Sherrod Brown, for his 
leadership on this issue. I was pleased to work with him on this 
important initiative in the previous two Congresses.
  The National Pediatric Research Network Act expands and enhances our 
Nation's commitment to pediatric research by providing the 
infrastructure that is needed to advance the field for decades to come. 
To do so, the law includes training and support for early-career 
investigators and authorizes the National Institutes of Health to 
select a number of competitive pediatric research consortia. Each 
consortium, comprised of multiple institutions, will focus on specific, 
high-impact pediatric research, including basic, translational, and 
clinical investigations.
  In addition, the law specifically states that a subset of the 
consortia must focus primarily on pediatric rare diseases. 
Participating institutions are encouraged to coordinate with multi-site 
clinical trials of pediatric patient populations. This will provide 
needed support for the families of children suffering from rare 
diseases, such as Duchenne muscular dystrophy, the most common fatal 
genetic disorder diagnosed in childhood, and spinal muscular atrophy, 
the leading genetic killer of children under the age of 2.
  The National Pediatric Research Network Act's collaborative approach 
allows us to rethink and improve the way pediatric research is 
conducted. Shared resources among pediatric institutions help maximize 
the government's return on investment and avoid duplication. Rather 
than allocating additional funds at the taxpayers' expense, the law 
seeks to accelerate treatments for pediatric diseases by emphasizing 
collaboration and the efficient use of limited Federal resources.
  I wish to thank the many families and organizations in Mississippi 
and across the country that helped build the bipartisan support 
necessary for passage of this bill, including Children's Healthcare of 
Mississippi, FightSMA, Parent Project Muscular Dystrophy, the Coalition 
for Pediatric Medical Research, Children's Hospital Association, 
National Organization for Rare Disorders, National Down Syndrome 
Society, the Federation of Pediatric Organizations, and the Kakkis 
EveryLife Foundation.
  Simply put, this law will result in an improved and coordinated NIH 
pediatric research investment. This effort will help children across 
our Nation overcome numerous devastating diseases and conditions. I 
look forward to

[[Page 19425]]

working with my colleagues to ensure the timely and effective 
implementation of this law, and I will continue to fight for the health 
and well-being of our children.

                          ____________________